Post Kidney Transplant: Hypertension
Hypertension is common among kidney transplant recipients. Uncontrolled blood pressure in the kidney transplant recipients is associated with increased cardiovascular mortality and morbidity, and decreased graft survival. The Kidney Disease: Improving Global Outcomes (KDIGO) and American Society of Transplantation (AST) guidelines recommended a target blood pressure ≤130/80 in kidney transplant recipients. In this book chapter, we reviewed the available evidence based on randomized clinical trials and large observational studies in kidney transplant recipients. Based on the available data, it can be concluded: (a) a blood pressure target of ≤130/80 is a reasonable goal as suggested by KDIGO; (b) the choice of antihypertensive agent should be based on the patients’ other comorbidities; and (c) achieving good blood pressure control is more important than the choice of the antihypertensive agent.
KeywordsHypertension Kidney transplant recipients Blood pressure targets Antihypertensives
- 1.Available from: https://www.usrds.org/2012/view/default.aspx.
- 9.Guidi E, Menghetti D, Milani S, Montagnino G, Palazzi P, Bianchi G. Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families. J Am Soc Nephrol. 1996;7(8):1131–8.PubMedGoogle Scholar
- 29.van Riemsdijk IC, Mulder PG, de Fijter JW, Bruijn JA, van Hooff JP, Hoitsma AJ, et al. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Transplantation. 2000;70(1):122–6.PubMedGoogle Scholar
- 33.Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349(9069):1857–63.Google Scholar
- 35.Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.Google Scholar